Stockhub

CEL-SCI Corporation: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 August 2022

5 August 2022

  • curprev 17:4517:45, 5 August 2022‎ Paris talk contribs‎ 993 bytes +993‎ Created page with "CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections,..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/CEL-SCI_Corporation’